Clinic
Agnesian Healthcare, INC
Agnesian Healthcare, INC was paid $17.74M by Medicaid between Jan 2018 and Dec 2024, across 293 billing codes. Its largest line is 99283, emergency room visit (moderate) — 9.6% of everything it billed.
33Billing provider infoAGNESIAN HEALTHCARE, INC
FOND DU LAC, WI 54935
FOND DU LAC, WI 54935
33aNPI1346228541assigned 01/06/2006
33bProvider typeAdult Day Care Clinic/Center
28Total paid$17.74M
24GClaims912,311
24DCodes billed293
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Adult Day Care Clinic/Center providers in Wisconsin
Rank by total paid#1 of 7
Median peer was paid$178K
This provider vs. median100×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official GRINNELL, AMY controls 11+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 132,710 | $2.75M | |
| 2019 | 130,170 | $2.84M | |
| 2020 | 112,251 | $2.14M | |
| 2021 | 141,402 | $2.38M | |
| 2022 | 142,937 | $2.58M | |
| 2023 | 148,562 | $2.78M | |
| 2024incomplete | 104,279 | $2.27M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.6% | 31,695 | 26,884 | $1.70M |
| 96361 | Intravenous infusion, hydration; each additional hour | 8.2% | 13,548 | 9,634 | $1.45M |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 7.0% | 28,911 | 14,453 | $1.24M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.1% | 20,337 | 16,903 | $896K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.9% | 14,268 | 12,663 | $868K |
| 80053 | Comprehensive metabolic panel | 4.2% | 31,582 | 24,188 | $743K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.2% | 27,198 | 9,341 | $741K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 5,707 | 4,959 | $362K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 6,732 | 5,760 | $356K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.0% | 6,939 | 5,519 | $350K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 6,100 | 3,474 | $299K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.7% | 2,616 | 2,255 | $297K |
281 more codes
| 85610 | 1.6% | 20,784 | $280K | |
| 84484 | 1.5% | 16,385 | $266K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.5% | 14,468 | $266K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.4% | 1,589 | $254K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.4% | 3,571 | $244K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.4% | 8,991 | $240K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.3% | 8,531 | $239K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.3% | 6,895 | $237K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.3% | 3,413 | $237K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 40,699 | $226K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.1% | 11,458 | $202K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.1% | 7,944 | $201K |
| 99285 | Emergency room visit (most serious) | 1.1% | 4,749 | $193K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.0% | 5,301 | $178K |
| 59025 | Fetal non-stress test | <1% | 2,202 | $175K |
| 80306 | <1% | 7,111 | $169K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 5,559 | $154K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,242 | $147K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,275 | $146K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,901 | $145K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,346 | $137K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,980 | $132K |
| 83880 | <1% | 4,817 | $132K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,633 | $128K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,487 | $108K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,318 | $107K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,353 | $96K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,021 | $93K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,449 | $85K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 751 | $85K |
| G0378 | Hospital observation service, per hour | <1% | 4,980 | $84K |
| 87631 | <1% | 610 | $83K | |
| H0022 | Alcohol and/or drug intervention service (planned facilitation) | <1% | 5,637 | $82K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 258 | $79K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 955 | $77K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,198 | $74K |
| 97162 | <1% | 2,727 | $73K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 376 | $67K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,385 | $67K |
| 97161 | <1% | 2,125 | $65K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,794 | $61K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,896 | $61K |
| 74018 | <1% | 3,129 | $60K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,932 | $59K |
| 83690 | <1% | 11,230 | $58K | |
| 84703 | <1% | 7,691 | $58K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 1,089 | $57K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,657 | $56K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,852 | $55K |
| 81001 | <1% | 16,213 | $54K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 999 | $50K |
| 93971 | <1% | 1,563 | $48K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 809 | $45K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,976 | $44K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 8,567 | $43K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 1,127 | $43K |
| 81025 | <1% | 3,884 | $42K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,074 | $41K |
| 87081 | <1% | 2,422 | $41K | |
| 83735 | <1% | 9,778 | $41K | |
| 84145 | <1% | 2,479 | $40K | |
| 82077 | <1% | 4,339 | $39K | |
| 93017 | <1% | 1,025 | $39K | |
| 83605 | <1% | 5,263 | $38K | |
| 87800 | <1% | 1,517 | $37K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 238 | $37K |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | <1% | 636 | $35K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 398 | $34K |
| 90837 | Psychotherapy session, about an hour | <1% | 1,309 | $32K |
| 80143 | <1% | 2,934 | $30K | |
| 80179 | <1% | 2,857 | $29K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 1,077 | $29K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 536 | $28K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 17,469 | $27K |
| 85730 | <1% | 7,301 | $26K | |
| 87040 | <1% | 3,057 | $25K | |
| 72100 | <1% | 1,768 | $25K | |
| Q3014 | Telehealth originating site facility fee | <1% | 5,757 | $24K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 424 | $24K |
| 87077 | <1% | 2,511 | $23K | |
| 71250 | <1% | 823 | $23K | |
| 82805 | <1% | 834 | $21K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,106 | $21K |
| 76830 | Ultrasound, transvaginal | <1% | 744 | $21K |
| 93296 | <1% | 1,353 | $20K | |
| 84702 | <1% | 890 | $19K | |
| 85379 | <1% | 2,855 | $19K | |
| 94726 | <1% | 964 | $19K | |
| 76770 | <1% | 470 | $18K | |
| 87186 | <1% | 2,159 | $17K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,746 | $17K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 64 | $16K |
| 97166 | <1% | 624 | $16K | |
| 70498 | <1% | 196 | $15K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 252 | $15K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 20,909 | $15K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 255 | $13K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,709 | $13K |
| 87632 | <1% | 71 | $13K | |
| 93976 | <1% | 423 | $13K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,201 | $13K |
| 70496 | <1% | 164 | $12K | |
| 97035 | <1% | 1,275 | $12K | |
| 73630 | <1% | 1,802 | $12K | |
| 87070 | <1% | 613 | $11K | |
| 73030 | <1% | 1,306 | $11K | |
| 73560 | <1% | 498 | $10K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 1,740 | $10K |
| 94060 | <1% | 336 | $10K | |
| 81003 | <1% | 3,383 | $10K | |
| 86850 | <1% | 1,812 | $10K | |
| 82962 | <1% | 1,446 | $9K | |
| 85027 | <1% | 1,818 | $9K | |
| 73130 | <1% | 1,250 | $9K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 72 | $8K |
| 76642 | <1% | 215 | $8K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 154 | $8K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,861 | $8K |
| 43249 | <1% | 53 | $8K | |
| 94660 | <1% | 169 | $8K | |
| 85378 | <1% | 1,169 | $8K | |
| 51701 | <1% | 634 | $7K | |
| 82330 | <1% | 625 | $7K | |
| 73610 | <1% | 1,383 | $7K | |
| 93970 | <1% | 174 | $6K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,453 | $6K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 499 | $6K |
| 97165 | <1% | 259 | $6K | |
| 94729 | <1% | 1,013 | $5K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 91 | $5K |
| 73564 | <1% | 1,331 | $5K | |
| 86140 | <1% | 1,369 | $5K | |
| 86900 | <1% | 2,368 | $5K | |
| 86901 | <1% | 2,409 | $5K | |
| 73110 | <1% | 516 | $5K | |
| 73502 | <1% | 533 | $5K | |
| 76536 | <1% | 122 | $5K | |
| 92523 | <1% | 50 | $5K | |
| 82550 | <1% | 1,033 | $4K | |
| 80061 | Lipid panel | <1% | 509 | $4K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 13 | $4K |
| 84100 | <1% | 872 | $4K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 59 | $4K |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 158 | $4K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 247 | $4K |
| H2012 | Behavioral health day treatment, per hour | <1% | 97 | $4K |
| 72141 | <1% | 72 | $4K | |
| 82565 | <1% | 1,241 | $3K | |
| 96137 | <1% | 37 | $3K | |
| 90715 | <1% | 494 | $3K | |
| 62323 | <1% | 29 | $3K | |
| 76801 | <1% | 191 | $3K | |
| 72050 | <1% | 143 | $3K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 14 | $3K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 87 | $3K |
| 93880 | <1% | 109 | $3K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 70 | $2K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 446 | $2K |
| 29125 | <1% | 27 | $2K | |
| 93226 | <1% | 104 | $2K | |
| 96136 | <1% | 37 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,978 | $2K |
| 77080 | <1% | 160 | $2K | |
| 87634 | <1% | 13 | $2K | |
| 87205 | <1% | 594 | $2K | |
| 80076 | <1% | 184 | $2K | |
| 97116 | <1% | 137 | $2K | |
| 97803 | <1% | 235 | $1K | |
| 75574 | <1% | 18 | $1K | |
| 77091 | <1% | 158 | $1K | |
| 85652 | <1% | 725 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 52 | $1K |
| 36592 | <1% | 708 | $978.92 | |
| 82800 | <1% | 131 | $918.78 | |
| 85014 | <1% | 842 | $915.50 | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 126 | $874.17 |
| 96367 | <1% | 31 | $841.12 | |
| 87641 | <1% | 49 | $837.07 | |
| 93922 | <1% | 53 | $812.19 | |
| 84439 | <1% | 139 | $808.92 | |
| 70491 | <1% | 14 | $722.78 | |
| 71101 | <1% | 15 | $710.54 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 47,052 | $700.39 |
| 84132 | <1% | 615 | $628.06 | |
| 93325 | <1% | 28 | $616.30 | |
| 87088 | <1% | 109 | $605.36 | |
| 73080 | <1% | 92 | $537.50 | |
| 84295 | <1% | 520 | $516.11 | |
| 82010 | <1% | 64 | $514.45 | |
| 93225 | <1% | 28 | $493.64 | |
| 94010 | <1% | 30 | $446.24 | |
| 95806 | <1% | 12 | $436.75 | |
| 80164 | <1% | 12 | $401.62 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 547 | $365.60 |
| 71271 | <1% | 16 | $268.70 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 13 | $231.01 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,067 | $201.78 |
| 96376 | <1% | 5,280 | $185.03 | |
| 84520 | <1% | 73 | $163.48 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 205 | $158.07 |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 25 | $152.92 |
| C1769 | Guide wire | <1% | 495 | $144.69 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,016 | $132.21 |
| 94762 | <1% | 17 | $130.34 | |
| 82607 | <1% | 17 | $118.90 | |
| 74019 | <1% | 27 | $92.85 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 15,148 | $84.60 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,904 | $67.77 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 882 | $66.97 |
| 99292 | <1% | 17 | $65.98 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,269 | $62.86 |
| 82570 | <1% | 17 | $59.66 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,928 | $45.85 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 11,064 | $42.76 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,879 | $38.32 |
| 99152 | <1% | 413 | $35.34 | |
| 85347 | <1% | 22 | $31.38 | |
| J2704 | Injection, propofol, 10 mg | <1% | 5,582 | $30.40 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,329 | $29.59 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,790 | $28.42 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 12,666 | $26.47 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,157 | $24.87 |
| 88307 | <1% | 14 | $23.90 | |
| 80050 | General health panel | <1% | 338 | $22.98 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,138 | $22.29 |
| 99153 | Mod sedat endo service >5yrs | <1% | 817 | $18.69 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,348 | $13.29 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 489 | $9.99 |
| 88304 | <1% | 70 | $9.77 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,833 | $8.39 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 449 | $5.80 |
| J7070 | Infusion, d5w, 1000 cc | <1% | 612 | $4.43 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,701 | $3.49 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,062 | $2.49 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,414 | $2.19 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,251 | $2.17 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 612 | $2.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 300 | $1.76 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,842 | $0.14 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 3,317 | $0.05 |
| J1815 | Injection, insulin, per 5 units | 0% | 58 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 61 | $0.00 |
| A9270 | Non-covered item or service | 0% | 2,723 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 352 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 344 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 231 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 632 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 176 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 205 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 969 | $0.00 |
| J3490 | Unclassified drugs | 0% | 180 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 163 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 44 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 258 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 22 | $0.00 |
| 88342 | 0% | 129 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 25 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 59 | $0.00 |
| 51798 | 0% | 19 | $0.00 | |
| S5136 | Companion care, adult (e.g., iadl/adl); per diem | 0% | 209 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 15 | $0.00 |
| 73090 | 0% | 12 | $0.00 | |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 18 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 246 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 2,451 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 1,931 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 217 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 1,148 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 440 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 534 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 3,911 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 241 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 98 | $0.00 |
| G8989 | Self care functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 35 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 168 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 42 | $0.00 |
| 73590 | 0% | 12 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 22 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 70 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 46 | $0.00 |
| 51702 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGRINNELL, AMY (VP-FINANCE, CFO)
| Provider | Location | Paid |
|---|---|---|
| Dean Health Systems, INC | Madison, WI | $26.19M |
| Agnesian Healthcare INC | Fond Du Lac, WI | $7.40M |
| Dean Health Systems, INC | Madison, WI | $919K |
| Dean Health Systems, INC. | Madison, WI | $856K |
| Dean Health Systems, INC. | Sun Prairie, WI | $750K |
| Dean Retail Services, INC. | Janesville, WI | $106K |
| Dean Retail Services, INC. | Sun Prairie, WI | $65K |
| Dean Retail Services, INC. | Madison, WI | $65K |
| Dean Retail Services, INC. | Stoughton, WI | $6K |
| Dean Retail Services, INC. | Sun Prairie, WI | $5K |
| Dean Retail Services, INC. | Waunakee, WI | $4K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.